Ewopharma and CStone enter into a strategic partnership for sugemalimab in Central Eastern Europe and Switzerland
Schaffhausen, Švicarska, 27. maj 2024 – Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Under the agreement, Ewopharma will gain the commercial rights for sugemalimab in Switzerland and 18 Central Eastern European countries … Read more